nivolumab,ipilimumab
bms
['nivo', 'niche-2']
 2022 presidential session - niche-2 study presented by : outstanding, game-changing waterfall plot of neoadjuvant #immunotherapy (nivo-ipi) in localized (albeit high-risk) msi/dmmr colon cancer. no postop recurrence to date! (although fu is only 13mo) 
GI oncologist, MD, PhD (FRA)